The quarter missed on reported earnings. Immunome posted a net loss of $0.65 per share versus published estimates around a $0.51 loss, while revenue was zero versus $4.0 million a year earlier. The larger-than-expected loss reflects sharply higher development spending rather than a new operating setback. (Statements of Operations)
| Metric | Q2 2026 | Q2 2025 / expectation |
|---|---|---|
| Collaboration revenue | $0.0 million (Statements of Operations) | $4.0 million (Statements of Operations) |
| Research and development expense | $59.9 million (Statements of Operations) | $40.5 million (Statements of Operations) |
| General and administrative expense | $18.3 million (Statements of Operations) | $10.0 million (Statements of Operations) |
| Net loss | $73.1 million (Statements of Operations) | $43.4 million (Statements of Operations) |
| Net loss per share | $0.65 loss (Statements of Operations) | $0.50 loss (Statements of Operations); approximately $0.51 loss consensus |
| Cash, cash equivalents and marketable securities | $520.0 million (Balance Sheets / Financial Results) | Cash runway stated into 2028 (Financial Results) |
The most important clinical and regulatory updates were largely confirmations, not fresh surprises. The FDA’s acceptance of varegacestat’s NDA and the April 28, 2027 PDUFA date reduce regulatory uncertainty, while the RINGSIDE results remain strong: an 84% reduction in progression or death risk and a 56% objective response rate versus 9% for placebo. However, both the acceptance and detailed ASCO data had already occurred before this August 11 filing, so the release mainly formalizes known milestones. (Pipeline Highlights — Varegacestat)
The pipeline is broadening, but the new programs are still early and unproven. IM-1617 and IM-3050 have begun Phase 1 dosing, and IM-1021 has shown responses in lymphoma participants, but the filing provides no new clinical data, timelines for efficacy readouts, or evidence that these assets have materially changed their probability of success. (Pipeline Highlights — IM-1021, IM-1617 and IM-3050)
Net read: a modest negative versus expectations, with the core investment case intact. The reported loss was worse than consensus, and the release does not introduce a new clinical upside surprise because the headline varegacestat developments were already public. The offset is a substantial $520 million cash position expected to fund operations into 2028, leaving Immunome financed through the next major regulatory and pipeline milestones. (Financial Results; Balance Sheets)
Read the original 8-K on SEC EDGAR ↗